dc.contributor.author | Kim, Nina H | |
dc.contributor.author | Scott, John | |
dc.contributor.author | Cent, Anne | |
dc.contributor.author | Cook, Linda | |
dc.contributor.author | Morrow, Rhoda Ashley | |
dc.contributor.author | et al | |
dc.date.accessioned | 2013-05-12T09:41:38Z | |
dc.date.available | 2013-05-12T09:41:38Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | J Viral Hepat. 2011 October; 18(10): e447–e452. | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/22387 | |
dc.description | Full text | en |
dc.description.abstract | Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV-HBV co-infected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV-infected adults before and for 18 months after starting highly-active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty-seven (6.9%) were HBsAg(+) and anti-HBs negative: 24 were HBeAg-negative, 18 had HBV DNA ≤10,000 IU/ml. Sustained HBV suppression to <100 IU/ml occurred in 89% of 19 evaluable patients. Resistance occurred in only 2 subjects, both with high baseline HBV DNA levels. Lamivudine resistance can emerge in the setting of incomplete HBV suppression but was infrequently observed among HIV-HBV co-infected patients with low baseline HBV DNA levels. | en |
dc.language.iso | en | en |
dc.subject | HIV-1 | en |
dc.subject | Lamivudine resistance | en |
dc.title | HBV Lamivudine Resistance among Hepatitis B and HIV Co-infected Patients Starting Lamivudine, Stavudine and Nevirapine in Kenya | en |
dc.type | Article | en |